Analyst consensus

The consensus estimates are collected by the company and based on the estimates of brokerage firms covering GlaxoSmithKline. Please ensure you have read and acknowledged the disclaimer prior to reviewing the information provided.

FY2019-2023 figures are as at 30/06/2019

All figures shown are on an Adjusted basis unless stated. 

Please select...
£m (unless stated) 2019 2020 2021 2022 2023 2019-2023 n=
Turnover 31,802 34,676 36,109 37,590 39,008 10
Cost of sales (9,485) (10,312) (10,649) (10,973) (11,306) 10
Selling, general and administration (9,936) (10,743) (10,955) (11,220) (11,516) 10
Research and Development (4,260) (4,626) (4,811) (4,973) (5,127) 10
Royalty income 300 285 278 277 276 10
Operating profit 8,424 9,279 9,972 10,701 11,335 10
Net finance costs (906) (908) (861) (830) (800) 10
Associates 58 21 21 22 22 10
Profit before tax 7,576 8,392 9,132 9,893 10,558 10
Taxation (1,442) (1,602) (1,745) (1,890) (2,017) 10
Profit after tax  6,134 6,790 7,387 8,003 8,541 10
Minority interests* (621) (1,129) (1,222) (1,312) (1,372) 10
Profit attributable to shareholders 5,513 5,661 6,165 6,691 7,169 10
WANS (m) 4,939 4,956 4,973 4,987 5,001 10
Earnings per share (p) 111.6 114.2 124.0 134.2 143.4 10
Dividend per share (p) 80.2 80.2 80.3 80.9 81.9 10
Free Cash Flow 3,069 4,085 4,622 5,309 5,870 7
Net Debt (25,624) (24,222) (23,376) (21,861) (19,878) 9

*All of the contributing firms have reflected the Consumer Healthcare JV with Pfizer

The firms included are: Bank of America Merrill Lynch, Barclays, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, Morgan Stanley, UBS, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Anoro 520 559 600 629 651 10
Arnuity 45 49 53 56 58 10
Incruse 340 389 428 459 486 10
Relvar/Breo 1,033 1,035 1,048 1,060 1,069 10
Trelegy 443 685 935 1,115 1,266 10
Ellipta portfolio 2,380 2,717 3,064 3,319 3,530 10
Nucala 708 823 914 988 1,044 10
Total Respiratory 3,088 3,540 3,978 4,307 4,573 10
             
Tivicay 1,670 1,687 1,683 1,675 1,664 9
Triumeq 2,581 2,515 2,449 2,395 2,346 9
Juluca 334 424 497 557 607 8
Dovato 63 224 401 582 698 8
Dolutegravir based regimens 4,637 4,840 5,008 5,174 5,283 10
Cabotegravir +/- rilpivirine - 51 152 241 338 8
fostemsavir - 47 123 175 226 9
Epzicom/Kivexa 76 58 49 41 35 10
HIV 4,872 5,128 5,414 5,669 5,890 10
             
Benylsta 551 618 677 725 736 10
             
Zejula 256 385 523 662 801 10
             
Advair (US) 470 254 196 173 153 9
Seretide (ex US) 1,174 1,045 941 852 782 9
Seretide/Advair 1,644 1,299 1,138 1,025 935 10
Flixotide/Flovent 556 523 490 462 435 10
Ventolin 789 762 746 731 714 10
Avamys/Veramyst 322 334 343 347 315 10
Established Respiratory 3,567 3,166 2,953 2,791 2,617 10
Other Established Pharmaceuticals 4,711 4,499 4,275 4,087 3,899 10
Established Pharmaceuticals 8,278 7,664 7,228 6,878 6,516 10
             
belantamab mafodotin (GSK'916 BCMA) - 56 158 251 366 10
dostarlimab - 15 57 88 123 6
daprodustat - 2 36 87 154 9
             
Pharmaceuticals 17,047 17,403 18,094 18,794 19,504 10


The firms included are: Bank of America Merrill Lynch, Barclays, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, Morgan Stanley, UBS, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Bexsero 640 684 723 757 786 10
Menveo 243 256 268 281 294 10
Fluarix/Flulaval 546 564 582 599 617 10
Shingrix 1,421 1,787 2,031 2,308 2,516 10
Boostrix 544 558 571 584 597 10
Cervarix 114 121 126 131 134 10
Hepatitis 843 875 901 924 943 10
Infanrix, Pediarix 664 662 667 674 681 10
Rotarix 534 552 564 578 592 10
Synflorix 432 435 439 442 443 10
Vaccines 6,633 7,164 7,570 8,014 8,375 10


The firms included are: Bank of America Merrill Lynch, Barclays, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, Morgan Stanley, UBS, Wolfe Research

Turnover £m 2019 2020 2021 2022 2023 2019-2023 n=
Wellness (incl. Pfizer OTC) 4,342 6,761 6,983 7,201 7,425 9
Oral health 2,566 2,663 2,761 2,862 2,967 9
Nutrition 640 100 102 105 108 9
Skin Health 574 585 599 613 628 9
Consumer Health* 8,122 10,109 10,445 10,781 11,129 10

*All of the contributing firms have reflected the Consumer Healthcare JV with Pfizer

The firms included are: Bank of America Merrill Lynch, Barclays, Cowen, Credit Suisse, Deutsche Bank, Exane, Jefferies, Morgan Stanley, UBS, Wolfe Research

Back to top